<ul>
	<li><strong>Suicide/suicidal thoughts or clinical worsening</strong>: Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs.&nbsp;</li>
	<li><strong>Concomitant Illness</strong>:&nbsp;Quetiapine should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension. Quetiapine may induce orthostatic hypotension especially during the initial dose-titration period.&nbsp;</li>
	<li><strong>Seizures</strong>:&nbsp;As with other antipsychotics, caution is recommended when treating patients with a history of seizures.</li>
	<li><strong>Tardive Dyskinesia and Extrapyramidal Symptoms (EPS)</strong>: If signs and symptoms of tardive dyskinesia appear, dose reduction or discontinuation of Quetiapine should be considered.</li>
	<li><strong>Neuroleptic Malignant Syndrome</strong>: This syndrome has been associated with antipsychotic treatment. Quetiapine should be discontinued and appropriate medical treatment given.</li>
	<li><strong>QT Prolongation</strong>: As with other antipsychotics, caution should be exercised when Quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation.</li>
	<li><strong>Neutropenia</strong>: Severe neutropenia (&lt;0.5x109/L) has been uncommonly reported in Quetiapine clinical trials. Most cases of severe neutropenia have occurred within the first two months of starting therapy with Quetiapine.</li>
	<li><strong>Hyperglycemia &amp; diabetes mellitus</strong>: Increases in blood glucose and hyperglycaemia, and occasional reports of diabetes, have been observed in clinical trials with Quetiapine.</li>
</ul>